Clinical trial · Observational
Radiomics for Diagnosing Liver Diseases and Evaluating Progression
the Department of Medical Ultrasonics, Third Affiliated Hospital of Sun Yat-Sen University, 600 Tianhe Road, Guangzhou, China.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Liver diseases are worldwide problems. liver fibrosis and hepatocellular carcinoma are mostly concerned by clinicians. Radiomcis can improve diagnosis accuracy and evaluate disease progression. Hence,investors try to combine radiomics and ultrasound images together in order to improve diagnosis performances of liver fibrosis, benign and malignant tumor and progression after liver ablations.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatitis B / Liver Space-occupying Lesions / Patients After Ablation | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| radiomics | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- chronic hepatitis B patients
- description
- ultrasound and radiomics
- interventionNames
- Diagnostic Test: radiomics
- label
- patients with liver space occupying lesions
- description
- ultrasound and radiomics
- interventionNames
- Diagnostic Test: radiomics
- label
- patients undergo ablation
- description
- ablation, ultrasound and radiomics
- interventionNames
- Diagnostic Test: radiomics
Primary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
For chronic hepatitis patients to assess liver biopsy Inclusion Criteria: * HBsAg positive or HBV-DNA detected * agreed to undergo liver biopsy * agreed to participated in our study Exclusion Criteria: * combined with other liver disease(eg. HAV/HCV/HDV,alcoholic liver disease) * combined with HIV * combined with malignant liver space occupying lesions * liver transplantation * pregnant * the sample size of liver biopsy could not demand: length lower than 15mm, portal areas less than 6. For patients classified between benign and malignant tumor Inclusion Criteria: * patients diagnosed with liver space occupying lesions * with histology results of liver space occupying lesions. * agreed to participate in our study and signed informed consent. Exclusion Criteria: * ultrasound images cant meet the demand for analysis * without histology results For patients to estimate progression after ablation Inclusion Criteria: * patients diagnosed with hepatocellular carcinoma; * patients treated with ablation; * patients performed the contrast-enhanced ultrasonography before ablation; * patients who treated with transcatheter arterial chemoembolization (TACE) performed the contrast-enhanced ultrasonography performed before TACE; Exclusion Criteria: * patients with lack of US digital imaging data * loss to follow-up
References
Publications (0)
Data not yet available